Preclinical results support entinostat's role in targeting the tumor microenvironment
Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon ...
Jul 11, 2017
0
1